Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hightide Therapeutics Inc ( (HK:2511) ) has issued an announcement.
HighTide Therapeutics, Inc. has formally established a Nomination Committee of its board of directors, effective from the date its shares were listed on the Hong Kong Stock Exchange, to oversee the nomination and governance process for directors and senior management. The creation of this committee, and the related governance framework defining key roles and responsibilities, signals a further alignment with Hong Kong listing requirements and best practices in corporate governance, which may enhance transparency, board oversight and confidence among investors and other stakeholders.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 2511, focused on developing and commercializing therapeutic products, particularly in high-need disease areas, for global healthcare markets.
Average Trading Volume: 643,409
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.33B
For a thorough assessment of 2511 stock, go to TipRanks’ Stock Analysis page.